



EffeMarket



# Global Lupus Nephritis Market Report: 2026

---

July 2018

## **Table of Content**

- 1 Executive Summary**
- 2 Introduction**
  - Symptoms**
  - Diagnosis**
    - Clinical Features
    - Clinical Tests
  - Histologic Classification**
  - Pathogenesis**
  - Treatment**
  - Management Strategy**
  - Current Treatment Approach**
    - Biological agents in Lupus Nephritis
  - Complications**
- 3 Epidemiology**
  - Global Prevalence of Systemic Lupus Erythematosus & Lupus Nephritis
  - US Prevalence of Systemic Lupus Erythematosus & Lupus Nephritis
  - Europe Prevalence of Systemic Lupus Erythematosus & Lupus Nephritis
  - Japan Prevalence of Systemic Lupus Erythematosus & Lupus Nephritis
- 4 Market Outlook & Forecast**
  - Global Lupus Nephritis Market
  - Global Lupus Nephritis Generics/Off-label Drugs Market
  - Global Lupus Nephritis Novel Drugs Market
  - Global Lupus Nephritis Cost of Therapy
  - US Lupus Nephritis Market
- 5 Clinical Trial Analysis**
  - By Phase
  - By Sponsor
  - By Therapy Type

By Company

By Drugs

## **6 Product Profiles**

### **Current Therapies**

Benlysta (Belimumab)

CellCept (Mycophenolate mofetil or MMF)

Prograf (Tacrolimus)

HP Acthar

### **Emerging Therapies**

Orencia (Abatacept)

Lupuzor (IPP-201101)

Anifrolumab

Orelvo (Voclosporin)

Blisibimod

## **7 Patent Landscape**

Overall IP Trends in Lupus Market

Patent Trends by Focus Area

Key Patents in Lupus Nephritis Market

Lupus Nephritis Market Patent Trend by Key Players

RCC Market Patent Trend by Top Inventors

## **8 Market Dynamics**

### **Growth Drivers**

High Unmet Clinical Need

Increasing Black Population

Needs for Novel Biomarkers

Increasing Research Grants

### **Trends**

Adoption of Inorganic Growth Strategies

Need for Calcineurin Inhibitors (CNIs) in LN

## **Challenges**

Heterogeneity of Organ Manifestations

High Cost of Therapy

## **9 Company Profiles**

### **Aurinia Pharmaceuticals**

Business Overview

Financial Overview

### **ImmuPharma PLC**

Business Overview

Financial Overview

### **Roche**

Business Overview

Financial Overview

### **Bristol-Myers Squibb**

Business Overview

Financial Overview

### **Anthera Pharmaceuticals**

Business Overview

Financial Overview

## **10 About EffeMarket**

## **11 Disclaimer**

## **12 Contact US**

## List of Figures

- Figure 1: Algorithm for Kidney Biopsy in Patients with LN
- Figure 2: Molecular Pathogenesis of Lupus Nephritis and Potential Therapeutic Targets
- Figure 3: Current Induction and Maintenance Treatment Choices for Proliferative Lupus Nephritis
- Figure 4: Global Diagnosed Prevalent Cases of SLE; 2017-2026
- Figure 5: Global Prevalence of SLE by Regions; 2017
- Figure 6: Global Diagnosed Prevalent Cases of LN; 2017-2026
- Figure 7: Global Prevalence of LN by Regions; 2017
- Figure 8: Global Prevalence of SLE/LN Breakdown; 2017
- Figure 9: Global Prevalence of SLE/LN by Race/Ethnicity; 2017
- Figure 10: Global Prevalence of SLE/LN Breakdown; 2017
- Figure 11: Global Prevalence of SLE/LN by Race/Ethnicity; 2017
- Figure 12: Global Prevalence of SLE/LN by Severity; 2011-2015
- Figure 13: US Diagnosed Prevalent Cases of SLE; 2017-2026
- Figure 14: US Diagnosed Prevalent Cases of LN; 2017-2026
- Figure 15: EU5 Diagnosed Prevalent Cases of SLE; 2017-2026
- Figure 16: EU5 Diagnosed Prevalent Cases of LN; 2017-2026
- Figure 17: Japan Diagnosed Prevalent Cases of SLE; 2017-2026
- Figure 18: Japan Diagnosed Prevalent Cases of LN; 2017-2026
- Figure 19: Global LN Market by Value; 2010-2022
- Figure 20: Global LN Generics/Off-label Drugs Market by Value; 2010-2022
- Figure 21: Global LN Novel Drugs Market by Value; 2010-2022
- Figure 22: Global Average Annual Cost of LN per Patient; 2017
- Figure 23: LN Drugs Cost per Year in the US; 2017
- Figure 24: Clinical Trial Analysis by Phase
- Figure 25: LN Clinical Trial Analysis by Sponsor
- Figure 26: LN Clinical Trial Analysis by Therapy Type
- Figure 27: LN Clinical Trial Analysis by Company

Figure 28: LN Clinical Trial Analysis by Drugs  
Figure 29: Benlysta Mechanism of Action  
Figure 30: CellCept Mechanism of Action  
Figure 31: CellCept Market by Number of Patients in the US; 2005-2013  
Figure 32: Prograf Mechanism of Action  
Figure 33: Prograf Sales in Japan for LN; 2008-2011  
Figure 34: Prograf Mechanism of Action  
Figure 35: HP Acthar Sales; 2015-2017  
Figure 36: Patient Treated with HP Acthar; 2016  
Figure 37: Orencia Mechanism of Action  
Figure 38: Orencia Sales; 2014-2016  
Figure 39: Lupuzor Mechanism of Action  
Figure 40: Anifrolumab Mechanism of Action  
Figure 41: Voclosporin Sales for LN; 2020  
Figure 42: Blisibimod Mechanism of Action  
Figure 43: Publication Year Trend  
Figure 44: Top Earliest Priority Country Filing Trend  
Figure 45: LN- Patent Focus  
Figure 46: LN Patent Trend by Composition  
Figure 47: LN Patent Trend by Current Therapies  
Figure 48: LN Patent Trend by Emerging Therapies  
Figure 49: LN Patent Trend by Route of Administration  
Figure 50: Lupus Nephritis Patent Trend by Key Patent Holders (Legal Assignees)  
Figure 51: LN Patent Trend by Top Inventors  
Figure 52: : LN Remission Rates  
Figure 53: Black Population Growth; 1990-2016  
Figure 54: Aurinia Net Sales; 2013-2017  
Figure 55: ImmuPharma Revenue; 2014-2017  
Figure 56: ImmuPharma R&D Expenditure; 2013-2017  
Figure 57: Roche Net Sales; 2013-2017

Figure 58: Bristol-Myers Squibb Revenue; 2013-2017

Figure 59: Bristol-Myers Squibb Revenue; 2013-2017

Figure 60: Anthera Pharmaceuticals R&D Expenditure; 2013-2017

## List of Tables

Table 1: Histologic Classification of Lupus Nephritis

Table 2: Voclosporin Patents

Table 3: Comparison of Immunotherapies in Late-Stage Development for SLE and/or Lupus Nephritis

Table 4: Lupus Nephritis- Patent Focus (2007-2018)

Table 5: Lupus Nephritis Patent Trend by Composition (2007-2018)

Table 6: LN Patent Trend by Current Therapies (2007-2018)

Table 7: Lupus Nephritis Patent Trend by Emerging Therapies

Table 8: Key Patents in Lupus Nephritis Market

Table 9: Key Patent Holder Year Wise Patent Filing in Lupus Nephritis Market; 2007-2018

Table 10: Key Player Patent Filing by Focus area

Table 11: Key Player Patent Filing by Composition

Table 12: Key Player Patent Filing by Current Therapies

Table 13: Top Collaborations of the Assignees

Table 14: Top Inventors Association with Key Players

## Executive Summary

Systemic lupus erythematosus (SLE) or lupus is an autoimmune disorder wherein organs and cells experience damage primarily intervened by tissue binding autoantibodies and immune complexes. Lupus nephritis (LN) is a type of kidney disease caused by SLE. It is linked with significant morbidity and mortality in patients with SLE and substantial risk of disease progression to end-stage renal failure.

Lupus nephritis is a potential kidney disease with significant unmet clinical needs regardless of extensive clinical and translational research over the past decade resulting in only drug approval of Benlysta (belimumab) in 2011 for SLE. Although immunosuppression therapy has made it possible to control the disease with improved life expectancy and better quality of life. Current therapeutic options available in lupus nephritis market are off-label therapies that have undesirable side effects which will remain at the forefront of LN market. Increase R&D activity and the launch of new biologic drugs will boost the growth of the global lupus nephritis market. The launch of new pipeline drugs will satisfy the need for improved lupus nephritis medications and effective treatment management. In 2017, there were 560,320 diagnosed prevalent cases of SLE in the US, Japan, and EU5 (France, Germany, Italy, Spain, and the UK). LN accounts for about 20 percent of SLE patients. The US has the highest number of people diagnosed from LN in 2017, followed by Japan and the UK. The prevalence of lupus nephritis in Asian SLE patient population is much higher than in Caucasians. Thus, it represents large and well-defined market opportunity with very less competition and is projected to be worth US\$5.89 billion by 2019 at a CAGR of 19 percent. The growing prevalence of LN, awareness among patients, robust healthcare infrastructure, increased R&D activities, and new drug approvals, have propelled the growth of the market. Significant opportunities will remain in the market even after the launch of current pipeline drugs due to lack of disease understanding and specific diagnosis test.

The market is characterized by the presence of a large number of companies. Strong pipeline and inorganic growth strategies will intensify the level of competition among the market players. Companies should embrace the idea of targeting a smaller subset of the larger SLE population to gain market share as this strategy will be the best approach for clinical success of investigational products. The leading players in the market are



Roche, GSK, Bristol Myers Squibb, MedImmune and AstraZeneca. The other prominent players in the market are Amgen, Anthera Pharmaceuticals, Aurinia, ImmuPharma, Merck, and Teva Pharmaceuticals.

## **Key Questions Answered**

- Prevalence of Systemic Lupus Erythematosus in US, EU5 and Japan; 2017-2026
- Prevalence of Lupus Nephritis in US, EU5 and Japan; 2017-2026
- Global Prevalence of Systemic Lupus Erythematosus by Severity and Race
- Global Prevalence of Lupus Nephritis by Severity and Race
- Global Lupus Nephritis Market by Value; 2010-2022
- Global Lupus Nephritis Generics/Off-label Drugs Market by Value; 2010-2022
- Global Lupus Nephritis Novel Drugs Market by Value; 2010-2022
- Global Average Annual Cost of LN per Patient; 2017
- Lupus Nephritis Drugs Cost per Year in the US; 2017
- Clinical Trial Analysis of Lupus Nephritis
- Product Profile of Current Therapies: Benlysta, CellCept, Prograf and HP Acthar
- Product Profile of Pipeline Therapies: Orencia, Lupuzor, Anifrolumab, Orelvo and Blisibimod
- Detailed analysis of growth drivers, challenges and trends in Smart Pills market.
- Detailed Company Profiling of Key Market Players: Aurinia, ImmuPharma, Roche, BMS and Anthera.

## About EffeMarket

EffeMarket provides market and business research solutions to clients in over 20 industries through syndicated studies, custom research, consulting engagements and newsletters. Our experienced analyst and widespread network of experts ensures accuracy within studies and provides our patrons with extensively researched, fact-based insights that help you to take better decisions.

## Disclaimer

EffeMarket reports and their contents, including all the analysis and research containing valuable market information, are provided to a select group of customers in response to orders. Our customers acknowledge when ordering that EffeMarket reports including all research and insights in their entirety are for our customers' internal use and not for general publication or disclosure to third parties. The market information is based primarily on secondary research and interviews and therefore, is subject to changes. EffeMarket takes no responsibility for any incorrect information supplied to us through such sources.

## Contact US

For any questions and updates, please contact:

[Sales@effemarket.com](mailto:Sales@effemarket.com)

[Support@effemarket.com](mailto:Support@effemarket.com)

Website: [www.effemarket.com](http://www.effemarket.com)

**Phone:**

US: +1-972-256-8133

UK: +44-203-286-8233

IN: +91 120 4561797

**Address:** Effectual Knowledge Services Pvt. Ltd. B-55, Sector 2, Noida – 201301, U.P., India

US Office – New York

Effectual Knowledge Services, Inc. 425 Broadhollow Road, Suite 427, Melville | NY 11747